[5]Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-1316. doi:10.1093/jnci/91.15.1310 [6]Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA...
Barkardottir RB, Johannsson OT, Ejlertsen B, Sønderstrup IMH, Hovig E, Lænkholm AV, Hansen TVO, Olafsdottir GH, Rossing M, Jonasson JG, Sigurdsson S, Loman N, Nilsson MP, Narod SA, Tryggvadottir L. Breast cancer su...
Mahadevia H, Ponvilawan B, Al-Obaidi A, Buckley J, Subramanian J, Bansal D. Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report. Ther Adv Med Oncol. 2024 Mar 30;16:17588359241242406. doi:...
Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report. Ther Adv Med Oncol. 2024 Mar 30;16:17588359241242406. doi: 10.1177/17588359241242406. PMID: 38559611; PMCID: PMC10981852....
Cancer risks among BRCA1 and BRCA2 mutation carriers. British journal of cancer 2007; 96:11-5. DOI: 10.1038/sj.bjc.6603535. PMID: 17213823. 20.Slade D. PARP and PARG inhibitors in cancer treatment. Genes & develo...
Women with BRCA1 or BRCA2 mutations have an increased risk of developing ovarian cancer. Therefore, as part of The Cancer Genome Atlas (TCGA) project, Wei Zhang and colleagues undertook a "comprehensive analysis of genomic, epigenetic, and clinical data in the TCGA database to identify not ...
参考文献: Chen, Qijun et al. “Extrarenal Wilms tumor of the recto-vaginal septum with BRCA2 gene mutation: a case report.” International journal of clinical and experimental pathology vol. 16,10 309-313. 15 Oct. 2023
[5]Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-1316. doi:10.1093/jnci/91.15.1310 [6]Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA...
19. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. British journal of cancer 2007; 96:11-5. DOI: 10.1038/sj.bjc.6603535. PMID: 17213823 20. Slade D. PARP and PARG inhibitors in cancer treatment. Genes & development 2020; 34:360- ...
如果能够在突变携带者患病之前通过BRCA1/2基因检测筛选出突变携带者，则可以通过药物，增加筛查或手术等方式来预防数百万癌症的发生。2020年7月，英国玛丽皇后大学的科研人员在" Cancers"杂志上在线发表了题为"Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health ...